Cargando…

Pharmacoeconomic Analysis of Fixed-Dose Combinations of Proton Pump Inhibitors Available in India

Introduction The global proton pump inhibitors (PPIs) market was valued at US$ 2.9 billion in 2020 and is expected to exhibit a compound aggregated growth rate of 4.30% during the forecast period (2020-2027), as they are regularly prescribed for many gastrointestinal disorders, and the treatment usu...

Descripción completa

Detalles Bibliográficos
Autores principales: Deolekar, Pradnya, Vivek, Kavita, Ghosh, Souvik, Naseem, Azra, Srivathsan, Mayakalyani, Rai, Vivek S, Signapurkar, Sonal, Yadav, Pramila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098438/
https://www.ncbi.nlm.nih.gov/pubmed/37065352
http://dx.doi.org/10.7759/cureus.36112
_version_ 1785024810300997632
author Deolekar, Pradnya
Vivek, Kavita
Ghosh, Souvik
Naseem, Azra
Srivathsan, Mayakalyani
Rai, Vivek S
Signapurkar, Sonal
Yadav, Pramila
author_facet Deolekar, Pradnya
Vivek, Kavita
Ghosh, Souvik
Naseem, Azra
Srivathsan, Mayakalyani
Rai, Vivek S
Signapurkar, Sonal
Yadav, Pramila
author_sort Deolekar, Pradnya
collection PubMed
description Introduction The global proton pump inhibitors (PPIs) market was valued at US$ 2.9 billion in 2020 and is expected to exhibit a compound aggregated growth rate of 4.30% during the forecast period (2020-2027), as they are regularly prescribed for many gastrointestinal disorders, and the treatment usually lasts for a longer period. PPIs are usually combined with antiemetics and prokinetic drugs. The price of PPIs for the same combination varies a lot, which can lead to a lot of financial burden on the patients. Objective To evaluate the cost ratio and percentage cost variation of commonly used PPIs in various combinations. Methodology The cost of different brands of commonly used PPIs in combination with other drugs was analyzed in our study. A total of 21 different combinations (10 capsules/tablets for oral use) were tabulated by referring to the “Monthly Index of Medical Specialities” October-December 2021, and 1mg online pharmacy. The cost ratio and percentage cost variation for various brands of a particular strength and dosage form were calculated and compared. Cost ratio > 2 and cost variation > 100% were considered significant. Results The results show a huge variation (1788.88%) in costs of different brands with the highest being rabeprazole 20 mg and domperidone 10 mg (cost ratio: 18.88, percentage cost variation: 1788.88%) in oral formulation, followed by pantoprazole 40 mg and itopride 150 mg. The minimum cost ratio (1.35) and percentage cost variation (1.35%) is for pantoprazole 40 mg and levosulpiride 75 mg. Logistic regression analysis between the number of brands and percentage cost variation gives an R(2) value of 0.0923. Conclusion There is a wide variation in the prices of PPIs available in the market, which can inadvertently increase the financial burden of therapy on patients. Physicians need to be made aware of these price differences so that they can choose the best available alternative for patients, which can help in increasing compliance with the prescribed drugs.
format Online
Article
Text
id pubmed-10098438
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-100984382023-04-14 Pharmacoeconomic Analysis of Fixed-Dose Combinations of Proton Pump Inhibitors Available in India Deolekar, Pradnya Vivek, Kavita Ghosh, Souvik Naseem, Azra Srivathsan, Mayakalyani Rai, Vivek S Signapurkar, Sonal Yadav, Pramila Cureus Emergency Medicine Introduction The global proton pump inhibitors (PPIs) market was valued at US$ 2.9 billion in 2020 and is expected to exhibit a compound aggregated growth rate of 4.30% during the forecast period (2020-2027), as they are regularly prescribed for many gastrointestinal disorders, and the treatment usually lasts for a longer period. PPIs are usually combined with antiemetics and prokinetic drugs. The price of PPIs for the same combination varies a lot, which can lead to a lot of financial burden on the patients. Objective To evaluate the cost ratio and percentage cost variation of commonly used PPIs in various combinations. Methodology The cost of different brands of commonly used PPIs in combination with other drugs was analyzed in our study. A total of 21 different combinations (10 capsules/tablets for oral use) were tabulated by referring to the “Monthly Index of Medical Specialities” October-December 2021, and 1mg online pharmacy. The cost ratio and percentage cost variation for various brands of a particular strength and dosage form were calculated and compared. Cost ratio > 2 and cost variation > 100% were considered significant. Results The results show a huge variation (1788.88%) in costs of different brands with the highest being rabeprazole 20 mg and domperidone 10 mg (cost ratio: 18.88, percentage cost variation: 1788.88%) in oral formulation, followed by pantoprazole 40 mg and itopride 150 mg. The minimum cost ratio (1.35) and percentage cost variation (1.35%) is for pantoprazole 40 mg and levosulpiride 75 mg. Logistic regression analysis between the number of brands and percentage cost variation gives an R(2) value of 0.0923. Conclusion There is a wide variation in the prices of PPIs available in the market, which can inadvertently increase the financial burden of therapy on patients. Physicians need to be made aware of these price differences so that they can choose the best available alternative for patients, which can help in increasing compliance with the prescribed drugs. Cureus 2023-03-14 /pmc/articles/PMC10098438/ /pubmed/37065352 http://dx.doi.org/10.7759/cureus.36112 Text en Copyright © 2023, Deolekar et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Emergency Medicine
Deolekar, Pradnya
Vivek, Kavita
Ghosh, Souvik
Naseem, Azra
Srivathsan, Mayakalyani
Rai, Vivek S
Signapurkar, Sonal
Yadav, Pramila
Pharmacoeconomic Analysis of Fixed-Dose Combinations of Proton Pump Inhibitors Available in India
title Pharmacoeconomic Analysis of Fixed-Dose Combinations of Proton Pump Inhibitors Available in India
title_full Pharmacoeconomic Analysis of Fixed-Dose Combinations of Proton Pump Inhibitors Available in India
title_fullStr Pharmacoeconomic Analysis of Fixed-Dose Combinations of Proton Pump Inhibitors Available in India
title_full_unstemmed Pharmacoeconomic Analysis of Fixed-Dose Combinations of Proton Pump Inhibitors Available in India
title_short Pharmacoeconomic Analysis of Fixed-Dose Combinations of Proton Pump Inhibitors Available in India
title_sort pharmacoeconomic analysis of fixed-dose combinations of proton pump inhibitors available in india
topic Emergency Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098438/
https://www.ncbi.nlm.nih.gov/pubmed/37065352
http://dx.doi.org/10.7759/cureus.36112
work_keys_str_mv AT deolekarpradnya pharmacoeconomicanalysisoffixeddosecombinationsofprotonpumpinhibitorsavailableinindia
AT vivekkavita pharmacoeconomicanalysisoffixeddosecombinationsofprotonpumpinhibitorsavailableinindia
AT ghoshsouvik pharmacoeconomicanalysisoffixeddosecombinationsofprotonpumpinhibitorsavailableinindia
AT naseemazra pharmacoeconomicanalysisoffixeddosecombinationsofprotonpumpinhibitorsavailableinindia
AT srivathsanmayakalyani pharmacoeconomicanalysisoffixeddosecombinationsofprotonpumpinhibitorsavailableinindia
AT raiviveks pharmacoeconomicanalysisoffixeddosecombinationsofprotonpumpinhibitorsavailableinindia
AT signapurkarsonal pharmacoeconomicanalysisoffixeddosecombinationsofprotonpumpinhibitorsavailableinindia
AT yadavpramila pharmacoeconomicanalysisoffixeddosecombinationsofprotonpumpinhibitorsavailableinindia